Zziltivekimab· Health · 8 sources · Sep 7, 2026StoryNovo Nordisk Halts Two Ziltivekimab Heart TrialsNovo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.Health· Sep 7, 2026+502ShareRachel Meyers·Sep 7, 2026Top commentKind of telling that they're still holding onto that one post-MI study though. Guess we'll see if there's a specific subgroup where this actually works.00ReplyGenius replyShareWrite a comment…
